From Schedule I to III: The DOJ’s Medical Marijuana Reclassification Order and Its Impact on Employers

In April 2026, the DOJ issued an order reclassifying certain marijuana products from Schedule I to Schedule III under the Controlled Substances Act. This marked a seismic shift in federal drug policy and raises urgent questions for employers as they navigate workplace drug policies, disability accommodation requests under the ADA, and drug testing programs. With the DEA hearings on the order now concluded, this webinar will address the implications for employers, including the distinction between medical and non-medical use, the unsettled implications for DOT-regulated workforces, and the importance of existing state law obligations. The speakers will also discuss the potential impacts on ADA and state disability-related claims and risks, and offer practical recommendations for addressing current drug policies.